Large Prospective Lung Cancer Study to Be Presented at ESMO
Idylla reduced EGFR mutation testing turnaround time by more than a week versus reference methods for patients with NSCLC.
Read More
Search Results for: lung cancer
FDA Approves First NGS-Based CDx for RET Fusion-Positive NSCLC
Thermo Fisher Scientific’s Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.
Read More
FDA Approves FoundationOne Liquid CDx Liquid Biopsy Test
Foundation Medicine’s FoundationOne Liquid CDx is a pan-tumor liquid biopsy test for patients with solid tumors.
Read More
Thermo Fisher, Hengrui Therapeutics to Develop CDx for NSCLC
The companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients with HER2 mutations.
Read More
Study Focuses on Different Kind of Liquid Biopsy to Detect Cancer
Researchers report EVPs, tiny packages of materials released by tumors, may serve as biomarkers for detecting different types of cancer with liquid biopsy.
Read More